Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum Sells 4,000 Shares of Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now owns 309,565 shares in the company, valued at $2,786,085. This trade represents a 1.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Rhonda Farnum also recently made the following trade(s):

• On Monday, November 11th, Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock. The stock was sold at an average price of $9.00, for a total value of $36,000.00.

Theravance Biopharma Stock Performance

TBPH stock opened at $9.67 on Friday. Theravance Biopharma, Inc. has a twelve month low of $7.44 and a twelve month high of $10.44. The stock’s 50 day moving average is $9.45 and its 200-day moving average is $8.90.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The firm had revenue of $16.87 million for the quarter, compared to the consensus estimate of $16.11 million. During the same period in the previous year, the business earned ($0.17) earnings per share. As a group, equities analysts predict that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Theravance Biopharma

Hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC lifted its holdings in Theravance Biopharma by 1.1% during the third quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company’s stock worth $1,165,000 after acquiring an additional 1,640 shares during the period. SG Americas Securities LLC grew its position in Theravance Biopharma by 21.1% during the fourth quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 3,349 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Theravance Biopharma by 64.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 3,696 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Theravance Biopharma by 29.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,978 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 3,827 shares during the period. Finally, XTX Topco Ltd boosted its stake in Theravance Biopharma by 34.5% in the third quarter. XTX Topco Ltd now owns 20,439 shares of the biopharmaceutical company’s stock valued at $165,000 after acquiring an additional 5,243 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.